Engineered AAV Capsid P-Motif Targeting CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Recombinant adeno-associated viruses (rAAVs) with natural capsid variants have limited cell tropism, leading to inefficient delivery to the central nervous system (CNS) and requiring high doses, which can cause liver toxicity, and there are challenges in manufacturing therapeutic quantities for adult patients, with preclinical studies in mice not accurately reflecting results in primates due to species differences in gene expression and physiology.
Innovation Solution
Development of engineered AAV compositions with targeting moieties, such as n-mer inserts comprising P-motifs or double valine motifs, that enhance CNS specificity by modifying the AAV capsid to reduce uptake in non-CNS cells, allowing for more efficient and targeted gene delivery to the CNS while minimizing liver toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional rAAVs with natural capsid variants are used for CNS delivery, then the delivery vehicle is simple and well-established, but transduction efficiency in CNS cells is limited and high doses are required
Solution Approach 1:
The patent applies local quality by inserting specific amino acid sequences (n-mer inserts with P-motifs or double valine motifs) at particular locations within the AAV capsid protein structure. These localized modifications specifically enhance CNS cell recognition and uptake without altering the overall capsid structure, thereby improving transduction efficiency in target cells while maintaining compatibility with existing AAV production systems.
Solution Approach 2:
The patent employs parameter changes by systematically varying the amino acid sequences inserted into the capsid (different n-mer lengths, P-motif variations, double valine motif configurations) to optimize binding affinity and specificity for CNS cell surface receptors. This allows tuning of the capsid's biological properties to achieve superior transduction efficiency at lower doses.
2Reliability
If high doses of conventional rAAVs are administered to achieve CNS transduction, then adequate therapeutic dosage is achieved, but liver toxicity occurs
Solution Approach 1:
The localized capsid modifications create high specificity for CNS cell surface receptors, enabling the virus to selectively bind and enter CNS cells rather than hepatocytes. This selective targeting allows therapeutic doses to be delivered to the intended target while minimizing off-target accumulation in the liver, thereby reducing hepatotoxicity.
Solution Approach 2:
The engineered capsid acts as an intermediary that mediates specific recognition between the AAV vector and CNS cell surface receptors. This enhanced specificity serves as a selective gateway that directs the virus away from non-target organs like the liver and toward the central nervous system, reducing harmful off-target effects.
3Quantity of substance
If conventional rAAVs are used for therapeutic applications, then manufacturing processes are established, but manufacturing sufficient quantities for adult patients is extremely challenging
Solution Approach 1:
The patent maintains universality by using the well-established AAV production platform and cell culture systems. The capsid engineering approach is compatible with existing manufacturing processes, allowing the engineered AAVs to be produced using the same transfection, assembly, and purification workflows as conventional AAVs, thereby facilitating scalable manufacturing for adult patient doses.
Solution Approach 2:
The patent applies segmentation by separating the capsid design into modular components: the base AAV capsid structure remains intact while specific n-mer inserts are added as discrete elements. This modular approach allows for systematic optimization of individual insert sequences without redesigning the entire capsid, simplifying the engineering and manufacturing process.
4Ease of operation
If preclinical studies are conducted in mouse models, then initial testing is feasible, but results do not accurately reflect outcomes in primates due to species differences
Solution Approach 1:
The patent addresses species differences by optimizing capsid sequences specifically for primate CNS receptors. The n-mer inserts and motifs are selected and engineered based on their ability to bind primate-specific cell surface markers, thereby changing the biological recognition parameters to match primate physiology. This ensures that preclinical studies in non-human primates accurately predict human responses.
Solution Approach 2:
The patent uses non-human primate models as更接近 copies of human physiology compared to mouse models. By conducting preclinical studies in NHPs with the engineered capsids, the results more accurately replicate human CNS transduction patterns, reducing the translational gap between preclinical and clinical outcomes.
Data Source
AI summary
Described in several exemplary embodiments are compositions including a targeting moiety effective to target a central nervous system cell and formulations thereof. In certain embodiments, the targeting moiety is composed of a n-mer insert containing or being composed only of a P-motif. Also described in certain example embodiments are vector systems configured to generate polypeptides containing the one or more targeting moieties. Also described herein are methods of generating a targeting moiety effective to target a central nervous system cell and using the compositions containing the targeting moieties described herein, such as to deliver a cargo to a subject and/or treat a central nervous system disease, disorder, or system thereof.